IMTX Immatics NV

In a report released on September 5, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics (IMTX - Research Report). The company's shares closed yesterday at $12.76.Chang covers the Healthcare sector, focusing on stocks such as Immatics, ImmunoGen, and Adaptimmune Therapeutics. According to TipRanks, Chang has an average return of -11.2% and a 27.71% success rate on recommended stocks. Immatics has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.See Insiders’ Hot Stocks on TipRanks >> Based on Immatics' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $17.22 million and a GAAP net loss of $13.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-its-buy-rating-for-immatics-imtx?utm_source=advfn.com&utm_medium=referral